Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Merck & Co
(NY:
MRK
)
130.72
+3.72 (+2.93%)
Official Closing Price
Updated: 7:00 PM EDT, Apr 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Merck & Co
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Merck to Present Extensive New Research Demonstrating Significant Progress in the Treatment of Certain Earlier Stage Cancers and in Advancing Broad Oncology Pipeline at 2023 ASCO Annual Meeting
May 15, 2023
From
Merck & Co., Inc.
Via
Business Wire
3 Underperforming Nasdaq 100 Stocks Worth a Closer Look
May 04, 2023
Given the volatility and growth potential associated with the Nasdaq’s elite, investors may want to keep these recent underperformers on the watch list.
Via
MarketBeat
Topics
Stocks
Exposures
US Equities
Merck to Participate in Bank of America Securities 2023 Healthcare Conference
May 03, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck & Company Inc. (NYSE: MRK) Climbs to New 52-Week High
April 17, 2023
Via
Investor Brand Network
Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding
May 02, 2023
Can-Fite BioPharma Ltd. (NYSEAMERICAN: CANF) is an Israel-based biotechnology firm that develops small-molecule therapeutic treatments for cancers
Via
MarketBeat
High-Yield Pfizer Falls Off The COVID Cliff, And Survives
May 02, 2023
Pfizer is a value and high-yield compared to its peers and it it outperforming expectations in 2023; The pipeline is robust.
Via
MarketBeat
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE - UNVR)
May 01, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Update on FDA Advisory Committee Vote on LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer
April 28, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces First-Quarter 2023 Financial Results
April 27, 2023
From
Merck & Co., Inc.
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE – UNVR)
April 25, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE - UNVR)
April 18, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
North America Could Possibly Emerge as the Market Leader for Billion Dollar Detox Drinks Industry
April 18, 2023
EQNX::TICKER_START (NASDAQ:CELH),(NASDAQ:OMER),(NYSE:MRK),(NASDAQ:RXDX) EQNX::TICKER_END
Via
FinancialNewsMedia
Still 50% Upside To Go, Wall Street Is Getting Vaxcyte Right
April 18, 2023
When a biotech company delivers chart-busting news, more often follows. In a space that can be like throwing darts, Wall Street has bullseyes on Vaxcyte, Inc.
Via
MarketBeat
Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following
April 16, 2023
Via
ACCESSWIRE
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy Alone in Patients With Advanced or Unresectable Biliary Tract Cancer
April 16, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.
April 16, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.
April 16, 2023
From
Prometheus Biosciences
Via
GlobeNewswire
Novo Nordisk Charges Higher and Could be Just Getting Started
April 13, 2023
Novo Nordisk stock continues to move higher after announcing a partnership with Aspect Biosystems; but at 47x earnings this is still an expensive stock
Via
MarketBeat
FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
April 13, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck and Eisai Provide Update on Phase 3 Trials of KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) In Certain Patients With Advanced Melanoma (LEAP-003) and Metastatic Colorectal Cancer (LEAP-017)
April 07, 2023
From
Merck & Co., Inc.
Via
Business Wire
MRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III/IV
April 06, 2023
Via
ACCESSWIRE
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Padcev® (enfortumab vedotin-ejfv) for First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
April 03, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck to Hold First-Quarter 2023 Sales and Earnings Conference Call on April 27
March 30, 2023
From
Merck & Co., Inc.
Via
Business Wire
FDA Converts to Full Approval Indication for KEYTRUDA® (pembrolizumab) for Certain Adult and Pediatric Patients With Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors
March 29, 2023
From
Merck & Co., Inc.
Via
Business Wire
Don't Be Fooled by These 3 Value Traps
March 28, 2023
Approximately one out of every ten U.S. listed stocks have a positive P/E ratio less than 10. Some are justifiably cheap; others are merely fool’s gold.
Via
MarketBeat
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma, Regardless of Mismatch Repair Status
March 27, 2023
From
Merck & Co., Inc.
Via
Business Wire
BioNTech Is Ripe For A Rebound In 2023
March 27, 2023
BioNTech had a strong quarter and may become a takeover target due to its healthy pipeline and a looming patent cliff for big pharma.
Via
MarketBeat
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Merck Provides Update from Open-Label Arm of Phase 2 KeyVibe-002 Trial Evaluating MK-7684A, a Coformulation of Vibostolimab and Pembrolizumab, in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)
March 16, 2023
From
Merck & Co., Inc.
Via
Business Wire
Pfizer’s Latest Acquisition Strengthens the Case for PFE Stock
March 15, 2023
Pfizer's merger with Seagen will strengthen the company's already strong oncology portfolio and perhaps boost the case for owning PFE stock
Via
MarketBeat
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Advanced Malignant Pleural Mesothelioma
March 10, 2023
From
Merck & Co., Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.